3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Pancreatic Neoplasms
3
Urinary Bladder Neoplasms
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Sarcoma
1
Primary Myelofibrosis
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Interventions
Gemcitabine
25
Cisplatin
19
pembrolizumab
11
avelumab
10
Nivolumab
7
Mitomycin
6
Carboplatin
6
apaziquone
5
Paclitaxel
5
Vinblastine
4
Methotrexate
4
Doxorubicin
4
Docetaxel
4
BCG Vaccine
4
vofatamab
3
durvalumab
3
atezolizumab
3
Sunitinib
3
Standard of Care
3
Sorafenib
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Radiation
3
Magnetic Resonance Spectroscopy
3
Lapatinib
3
Cystectomy
3
B701 protein, Human herpesvirus 6
3
valrubicin
2
rucaparib
2
enfortumab vedotin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Urinary Bladder Neoplasms
×
rucaparib
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts
NCT03397394
2023-06-09
ATLAS
pharmaand GmbH
Phase 2
Terminated
97 enrolled
12 charts